Videos

"A lot of ancillary providers want more privileges that the physician has, and we have to be the guardians and the reason we're doing this is to protect our patients so that they get the best care available to them," says William C. Reha, MD, MBA.

“The frustration component that we found and heard amongst these women was with their providers really focusing their care around antibiotics…[and] not spending enough time on education with prevention strategies,” says Victoria C. Scott, MD.

“Being able to have a follow-up visit that is convenient, that saves time, that saves money, but that can allow you to put everything together for the patient…is still a very valuable tool,” says Juan José Andino, MD.

“The feedback has been very positive from both physicians and patients,” author Madeline Zech Ruiz says of her book “I Married a Urologist.”

“With more people using [telehealth], with more people essentially forced by the pandemic to have to offer care at least at some point virtually, there is comfort and…more interest in ensuring that it remains an option,” says Juan José Andino, MD.

“Everybody in our department participates in some quantity of telehealth within their regular scheduled practice,” says Kara L. Watts, MD, in this video.

Daniel C. Danila, MD, discusses choosing among the androgen receptor inhibitors darolutamide, enzalutamide, and apalutamide when treating patients with castration-resistant prostate cancer.

“[Telemedicine is] not just a form of health care delivery for emergency pandemic situations, this is something that is here to stay,” says Kara L. Watts, MD, in this video.

"None of our patients had unexpected appointments that had to be made after their video encounters…supporting this idea that at least in urology, it seems that telehealth is a substitute for inpatient care when appropriately selected by the physician,” says Juan José Andino, MD.

Jingsong Zhang, MD, PhD, discusses how the site of metastases impacts his approach to treatment selection for patients with metastatic castration-resistant prostate cancer.

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma.

Susan F. Slovin, MD, PhD, discusses the plethora of available treatment options and factors affecting treatment selection for patients with metastatic castration-sensitive prostate cancer.

Ninety-one percent of patients “felt very comfortable sharing sensitive information with the healthcare provider via the telehealth platform,” says Kara L. Watts, MD.

“It was quite a large subject to tackle,” Madeline Zech Ruiz says of her book, “I Married a Urologist.”

“Targeted ligand therapy is extremely exciting,” says Ketan K. Badani, MD.

Susan F. Slovin, MD, PhD, summarizes the key points urologists need to know about how PARP inhibitors are currently used in the prostate cancer paradigm.

Madeline Zech Ruiz discusses why she included chapters on premature ejaculation and genitourinary symptoms of menopause in her book “I Married a Urologist.”

“I would say, over the last several years, [MRI has] really become a popular thing to do prebiopsy,” says Ketan K. Badani, MD.

“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.

The targeted radioligand therapy achieved several other key end points beyond overall survival and radiographic progression-free survival.

“The…state of genomic testing continues to evolve,” says Ketan K. Badani, MD.

“What was surprising to us was that in both arms, about a third of the women really didn't have a urinary tract infection,” says Elizabeth R. Mueller, MD, MSME.

“I think as technology evolves, we as urologists need to continue to evolve and make changes to our practice,” says Kevin T. Keating, DO.

"I learned...over the first 10 years [of being married to a urologist] that everybody has a urology issue," says Madeline Zech Ruiz.

Pieczonka also discusses toxicity differences between VERU-111 and docetaxel.

“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.

The PSMA-PET imaging agents Piflufolastat F 18 and Gallium 68 PSMA-11 are approved by the FDA for managing patients with prostate cancer.

“We found in general that there was really no difference in their symptom improvement,” said Elizabeth R. Mueller, MD, MSME, of a study comparing women from whom standard vs expanded cultures were obtained.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

Christopher Pieczonka, MD, discusses where the novel agent sabizabulin (VERU-111) would fit in the metastatic castration-resistant prostate cancer paradigm if it succeeds in an ongoing phase 3 trial.